Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
Supply of Generic and Biosimilar Cancer Medicines to NHS Scotland.
No supplier information available.
This procurement was divided into 36 lots, each awarded separately.
| Lot | Value | Status |
|---|---|---|
| Lot 1 Bendamustine powder for solution for infusion vials Feb 2027 – Jan 2029 | £169,388 | active |
| Lot 2 Capecitabine tablets Feb 2027 – Jan 2029 | £590,765 | active |
| Lot 4 Cisplatin solution for infusion vials Feb 2027 – Jan 2029 | £1,008,289 | active |
| Lot 5 Cyclophosphamide powder for solution for injection vials Feb 2027 – Jan 2029 | £338,258 | active |
| Lot 6 Cytarabine solution for injection vials Feb 2027 – Jan 2029 | £122,307 | active |
| Lot 7 Dacarbazine powder for solution for injection/infusion vials Feb 2027 – Jan 2029 | £250,217 | active |
| Lot 8 Disodium folinate solution for injection vials Feb 2027 – Jan 2029 | £283,496 | active |
| Lot 9 Docetaxel solution for infusion vials Feb 2027 – Jan 2029 | £808,420 | active |
| Lot 11 Fluorouracil 25mg/ml solution for injection/infusion vials Feb 2027 – Jan 2029 | £231,402 | active |
| Lot 12 Fluorouracil 50mg/ml solution for injection/infusion vials Feb 2027 – Jan 2029 | £1,432,949 | active |
| Lot 13 Gemcitabine 38mg/ml solution for infusion vials Feb 2027 – Jan 2029 | £310,860 | active |
| Lot 14 Gemcitabine 100mg/ml solution for infusion vials Feb 2027 – Jan 2029 | £313,655 | active |
| Lot 15 Ifosfamide powder for solution for injection vials Feb 2027 – Jan 2029 | £1,759,061 | active |
| Lot 17 Methotrexate solution for injection/infusion vials Feb 2027 – Jan 2029 | £490,564 | active |
| Lot 18 Oxaliplatin solution for infusion vials Feb 2027 – Jan 2029 | £349,538 | active |
| Lot 19 Paclitaxel solution for infusion vials Feb 2027 – Jan 2029 | £2,541,766 | active |
| Lot 20 Temozolomide capsules Feb 2027 – Jan 2029 | £257,799 | active |
| Lot 21 Vincristine solution for injection vials Feb 2027 – Jan 2029 | £91,122 | active |
| Lot 22 Vinorelbine solution for infusion vials Feb 2027 – Jan 2029 | £24,630 | active |
| Lot 23 Aprepitant capsules Feb 2027 – Jan 2029 | £873,964 | active |
| Lot 24 Octreotide solution for injection ampoules Feb 2027 – Jan 2029 | £897,199 | active |
| Lot 25 Filgrastim solution for injection pre-filled syringes Feb 2027 – Jan 2029 | £4,796,431 | active |
| Lot 26 Pemetrexed powder for solution for infusion vials Feb 2027 – Jan 2029 | £14,436 | active |
| Lot 27 Pemetrexed solution for infusion vials Feb 2027 – Jan 2029 | £1,347,937 | active |
| Lot 29 Dasatinib tablets Feb 2027 – Jan 2029 | £1,038,368 | active |
| Lot 30 Azacitidine, bevacizumab, doxorubicin pegylated liposomal, lanreotide, octreotide, rituximab and trastuzumab lines Feb 2027 – Jan 2029 | £30,972,852 | active |
| Lot 31 Lenalidomide capsules Feb 2027 – Jan 2029 | £912,775 | active |
| Lot 32 Pomalidomide capsules Feb 2027 – Jan 2029 | £4,619,961 | active |
| Lot 33 Thalidomide capsules Feb 2027 – Jan 2029 | £428,163 | active |
| Lot 16 Irinotecan solution for infusion vials Feb 2027 – Jan 2029 | £751,953 | active |
Published by the buyer on this notice. Check the original notice — details change and are not updated here.